Treatment, Antimicrobial (Drug) Resistance - National Institute of ...
CARB-X prioritizes treatments for CDC and WHO-defined target pathogens, including C. difficile, MRSA, CRE, N. gonorrhoeae and Acinetobacter. Optimizing Existing Antibiotics. NIAID-supported clinical trials are testing optimized treatment regimens of older antibiotics to more effectively treat infections and suppress the emergence of resistance.
Antimicrobial (Drug) Resistance | NIAID: National Institute of …
Bacteria, fungi, and other microbes evolve over time and can develop resistance to antimicrobial drugs. Microbes naturally develop resistance; however, using antibiotics too often in humans and animals and in cases where antibiotics are not an appropriate treatment can make resistance develop more quickly.
Probiotic Markedly Reduces S. aureus Colonization in Phase 2 Trial
Jan 17, 2023 · A promising approach to control Staphylococcus aureus bacterial colonization in people—using a probiotic instead of antibiotics—was safe and highly effective in a Phase 2 clinical trial. The new study, reported in The Lancet Microbe, found that the probiotic Bacillus subtilis markedly reduced S. aureus colonization in trial participants without harming the gut microbiota, which includes ...
Eczema (Atopic Dermatitis) Treatment | NIAID: National Institute of ...
You and your doctor should discuss the best treatment plan and medications for your atopic dermatitis. But taking care of your skin at home may reduce the need for prescription medications. Some recommendations include . Relieve the itch by using a moisturizer. Antihistamines may help reduce severe itching.
Common Variable Immunodeficiency (CVID) | NIAID: National …
Apr 23, 2019 · Treatment. CVID is treated with intravenous immunoglobulin infusions or subcutaneous (under the skin) immunoglobulin injection to partially restore immunoglobulin levels. The immunoglobulin given by either method provides antibodies from the blood of healthy donors.
MRSA virulence. However, it should be noted that PVL is only one of many genes that are associated with CA-MRSA strains. Unfortu-nately, a preconceived notion that PVL is responsible for the prominence of CA-MRSA rapidly developed, although solid molecular evi-dence to support a function of PVL in CA-MRSA pathogenesis has never been pro-duced.
Rapid Diagnostics to Combat Antimicrobial Resistance
Nov 15, 2024 · Currently, broad spectrum antibiotics, which target a wide range of bacteria, are often prescribed when a diagnosis cannot be made prior to starting treatment. Diagnostics that identify the cause of an infection, as well as the susceptibility of that pathogen to specific antibiotics, can inform appropriate treatment, promote antibiotic ...
Fungal Disease-Specific Research - National Institute of Allergy …
In people with weakened immune systems, histoplasmosis can be severe and require long term antifungal treatment to resolve the disease. NIAID-supported researchers are identifying the pathways necessary for the fungi to establish infection and the human immune factors that are required to clear the infection.
The page you’re looking for isn’t available - National Institute of ...
It's possible that the page is temporarily unavailable, has been moved, renamed, or no longer exists. Here are some suggestions to find what you are looking for:
Antimicrobial Resistance Threats | NIAID: National Institute of …
Normally the microbes that live in the gut (called gut microbiota) can suppress C. diff-associated disease, but antibiotic treatment can deplete the microbiota in such a way that allows C. diff spores to germinate into vegetative cells which can produce up to three different toxins, causing extreme colonic inflammation. People at higher risk of ...